Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
RANCHO CORDOVA, Calif., Aug. 31, 2017 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will present at the CAR-TCR Summit 2017, which is being held September 6-7, 2017 at the Seaport Hotel & World Trade Center in Boston.
Jon Ellis, senior director of technical services at ThermoGenesis, Cesca’s device subsidiary, will deliver a spotlight presentation on ThermoGenesis’ automated CAR-T cell manufacturing capabilities on Thursday, September 7, 2017 at 10:40am ET during the “Tech Slam at the Innovation Hub.”
The CAR-TCR Summit brings together over 60 world-class speakers and more than 500 cell therapy experts in the only end-to-end conference dedicated to successfully bringing the next generation CAR-T & TCR cell immunotherapies to market. For more information, please visit http://car-tcr-summit.com.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc. Wendy Samford 916-858-5191 [email protected] Investor Contact: Rx Communications Paula Schwartz 917-322-2216 [email protected]
